Melika Amoukhteh

Melika Amoukhteh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2021 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
STSepehr Tohidi
Sepehr Tohidi
EBElham Bidabadi
Elham Bidabadi
MSMohammad Javad Khosousi Sani
Mohammad Javad Khosousi Sani
MAMelika Amoukhteh
Melika Amoukhteh
MKMaryam Kousha
Maryam Kousha
TSTamkin Shahraki
Tamkin Shahraki
Sepehr Tohidi, Elham Bidabadi, Mohammad-Javad Khosousi, Melika Amoukhteh, Maryam Kousha, Parham Mashouf, Tamkin Shahraki. Clin Psychopharmacol Neurosci 2021;19:712-20. https://doi.org/10.9758/cpn.2021.19.4.712

27 February 2025 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
JCJonathan Cortese
Jonathan Cortese
SGSherief Ghozy
Sherief Ghozy
PVParya Valizadeh
Parya Valizadeh
AHAlireza Hasanzadeh
Alireza Hasanzadeh
MAMelika Amoukhteh
Melika Amoukhteh
RKRam Kadirvel
Ram Kadirvel
Background: The Pipeline Vantage Flow diverter (Vantage) is the latest generation of Pipeline flow diverters introducing Cobalt-chronium drawn-filled tubing and 48 to 68 wires. Purpose: We report the initial safety and efficacy of Vantage in treating intracranial aneurysms in the published literature. Data Sources: A systematic review and meta-analysis was conducted according to established protocols. Searches were conducted in PubMed, Scopus, Web-of-Science, and Embase databases up to December 2023. Original studies reporting treatment outcomes for intracranial aneurysms using Vantage in more than five patients were included. Study Selection: Pooled data from 5 studies (373 patients, 418 aneurysms) were analyzed. Data Analysis: Outcomes of interest were: technical success, occlusion rates, complication outcomes and mortality. Data Synthesis: A technical success rate of 99.2% (95% CI: 98.29%–100%) was found. In unruptured cases, success rate was 378/383 (99.6%) versus 17/20 (85.0%) in ruptured cases (P < .01). Complete occlusion rate was 74.3% (95% CI: 67.43%–80.59%), with no significant difference between ruptured and unruptured cases (P = 0.72); median of follow up 6 months. Overall mortality rate was 1.2% (95% CI: 0.01%–3.64%), significantly higher in ruptured (18.6%; 95% CI: 5.13%–36.26%) versus unruptured cases (0.23%; 95% CI: 0%–1.36%) (P < 0.01). Hemorrhagic complications occurred at 1% (95% CI: 0%–3.36%) pooled rate. Thromboembolic complications were reported at 6.1% (95% CI: 2.60%–10.73%), decreasing to 4.35% (95% CI: 1.91%–7.54%) after excluding one outlier study. Limitations: Only five studies, some with small number of patients, were included in this meta-analysis which may limit the generalizability of our findings. The absence of long term follow-up also limits the assessment of treatment durability. Conclusions: In this meta-analysis, we found that Vantage initial experience is similar to previous version of the Pipeline Embolization Device in terms of safety and efficacy for treatment of intracranial aneurysms, in particular unruptured aneurysms. Further prospective and comparative studies with patient outcome data specific to aneurysm location are needed to confirm the safety and efficacy of Vantage.

20 July 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SGSherief Ghozy
Sherief Ghozy
HKHassan Kobeissi
Hassan Kobeissi
MAMelika Amoukhteh
Melika Amoukhteh
RKRam Kadirvel
Ram Kadirvel
WBWaleed Brinjikji
Waleed Brinjikji
DKDavid F. Kallmes
David F. Kallmes
Background: Stroke guideline statements are important references for clinicians due to the rapidly evolving nature of treatments. Guideline statements should be informed by up-to-date systematic reviews (SRs) and meta-analyses (MAs) because they provide the highest level of evidence. To investigate the utilization of SRs/MAs in stroke management guidelines, we conducted a literature review of guidelines and extracted relevant information regarding SRs/MAs. Methods: A literature review was conducted in PubMed with supplementation using the Trip medical database with the term “stroke” as the target population, followed by using the filter “guidelines”. We extracted the number of included SRs/MAs, the years of publication, the country of origin, and other characteristics of interest. Descriptive statistics were generated using the R software version 4.2.1. Results: We included 27 guideline statements. The median number of overall SRs or MAs within the guidelines was 4.0 (interquartile range [IQR] = 2–9). For MAs only, the median number included in the guidelines was 3.0 (IQR = 2.0–5.5). Canadian guidelines had the oldest citations, with a median gap of 12.0 (IQR = 5.2–18.0) years for the oldest citation, followed by European (median = 12; IQR = 9.5–13.5) and US (median = 10.0; IQR = 5.2–16) guidelines. Conclusions: Stroke guideline writing groups and issuing bodies should devote greater effort to the inclusion of up-to-date SRs/MAs in their guideline statements so that clinicians can reference recent data with the highest level of evidence.

25 September 2024 in Academic Radiology
Verified
Journal Article
Closed access
PVParya Valizadeh
Parya Valizadeh
PJPayam Jannatdoust
Payam Jannatdoust
AHAmir Valizadeh, Hassankhani
Amir Valizadeh, Hassankhani
MAMelika Amoukhteh
Melika Amoukhteh
PAPaniz Adli
Paniz Adli
AGAli Gholamrezanezhad
Ali Gholamrezanezhad